Evidence map›Paper›PMID 26651825›Full record

ArticleBMC pulmonary medicine2015

Clinical implications and characterization of Group A Streptoccoccus infections in adults with cystic fibrosis.

Kate Skolnik, Austin Nguyen, Ranjani Somayaji, Christina S Thornton, Barbara Waddell, Michael G Surette, Harvey R Rabin, Michael D Parkins

Open access · goldAbstract read
In one paragraph

Article in BMC pulmonary medicine, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.3field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Kate SkolnikDepartments of Medicine, The University of Calgary, Calgary, AB, Canada. Kate.Skolnik@albertahealthservices.ca.
Austin NguyenDepartments of Microbiology, Immunology and Infectious Diseases, The University of Calgary, 3330 Hospital Drive, NW, Calgary, AB, Canada. austinnguyen94@gmail.com.
Ranjani SomayajiDepartments of Medicine, The University of Calgary, Calgary, AB, Canada. ranjani.somayaji@albertahealthservices.ca.
Christina S ThorntonDepartments of Microbiology, Immunology and Infectious Diseases, The University of Calgary, 3330 Hospital Drive, NW, Calgary, AB, Canada. ceshaghu@ucalgary.ca.
Barbara WaddellDepartments of Microbiology, Immunology and Infectious Diseases, The University of Calgary, 3330 Hospital Drive, NW, Calgary, AB, Canada. bjmalber@ucalgary.ca.
Michael G SuretteDepartment of Medicine, McMaster University, Hamilton, ON, Canada. surette@mcmaster.ca.
Harvey R RabinDepartments of Medicine, The University of Calgary, Calgary, AB, Canada. rabin@ucalgary.ca.
Michael D ParkinsDepartments of Medicine, The University of Calgary, Calgary, AB, Canada. mdparkin@ucalgary.ca.
University of Calgary · CAMcMaster University · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPersistent airway infection is a hallmark feature of cystic fibrosis (CF). However, increasingly it has been observed that non-classical pathogens may transiently infect CF lower airways. Streptococcus pyogenes (Group A Streptococcus; (GAS)) is an uncommon but potentially dangerous cause of community-acquired pneumonia. Our aim was to determine the incidence, natural history, and clinical impact of GAS infections in CF and phenotypically and genotypically characterize the isolates.

methodsWe retrospectively evaluated the Calgary Adult CF Clinic biobank to identify adults with at least one GAS isolate. Patient demographics, medical and pulmonary exacerbation (PEx) histories were evaluated. The primary outcome was PEx occurrence at incident GAS culture. Secondary outcomes evaluated were changes in lung function and PEx frequency following GAS isolation. Isolates were assessed for extra-cellular virulence factor production capacity and ability to produce quorum sensing (AI-2). Isolates were genotyped using pulse-field gel electrophoresis (PFGE).

resultsFifteen individuals who cultured GAS twenty times were identified. At the time of GAS isolation, 47% (7/15) of subjects experienced a PEx and half of these (4/7) were severe. Individuals were more likely to have a PEx at the time of the index GAS isolate compared to the preceding visit (RR = 6.0, 95% CI 0.82-43.0, p = 0.08), particularly if GAS was the numerically dominant sputum pathogen (RR = 6.5, 95% CI 1.00-43.0, p = 0.009). There were no changes in PEx frequency or rate of lung function decline following GAS. None of the patients developed chronic airways infection, bacteremia, necrotizing pneumonia or empyema. Susceptibility was universal to common anti-Streptococcal antibiotics and anti-Pseudomonal antibiotics commonly used in CF, with the exception of azithromycin. GAS isolates varied in their production of protease, DNase, and AI-2 but these did not correlate with PEx, and none produced elastase, chrondrotin sulfatase or H202. One patient had prolonged carriage with the same isolate and two patients had isolates with similar PFGE patterns.

conclusionsGAS was an uncommon lower respiratory pathogen of adults with CF. Identification of GAS in sputum was frequently associated with PEx, particularly when numerically dominant. However, transient GAS infection did not result in chronic infection nor appreciably change long-term disease trajectory.

Indexed as

AdolescentAdultAnti-Bacterial AgentsCystic FibrosisDisease ProgressionFemaleGenotypeHumansMaleMiddle AgedRespiratory SystemRetrospective StudiesSputumStreptococcal InfectionsStreptococcus pyogenesYoung AdultAnti-Bacterial Agents

Identifiers

PMID26651825
PMCPMC4676819
OpenAlexW2217629550

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.